Q1 2025 Abcellera Biologics Inc Earnings Call Transcript
Key Points
- AbCellera Biologics Inc (ABCL) is advancing its first-in-class therapeutic antibody, ABCL635, for non-hormonal treatment of vasomotor symptoms associated with menopause, targeting a significant unmet medical need.
- The company has a strong liquidity position with approximately $630 million in cash and equivalents, and $180 million in available committed government funding.
- ABCL635 has the potential to be a first-in-class antibody therapy in the NK3R class, with a market opportunity estimated to reach over $2 billion in annual sales.
- The company is transitioning from a platform company to a clinical-stage biotech, with two programs, ABCL635 and ABCL575, nearing clinical trials.
- AbCellera Biologics Inc (ABCL) is making significant investments in building clinical manufacturing capabilities, expected to be operational later this year.
- Revenue for the quarter was about $4 million, a significant decrease from $10 million in the same quarter of 2024, primarily due to a focus on internal and co-development programs.
- The company reported a net loss of approximately $46 million for the quarter, compared to a loss of around $41 million in the same quarter last year.
- There were no new molecules advancing into the clinic in the quarter, maintaining a cumulative total of 16 molecules to have reached the clinic.
- The development of four Trianni licensed molecules by Novarock has been paused, potentially impacting future revenue from downstream milestone fees and royalty payments.
- Research and development expenses increased to approximately $43 million, driven by investments in internal and co-development programs, contributing to the overall net loss.
Good afternoon and welcome to the Abcellera's first quarter 2025 business update and conference call.
My name is Jasmine and I will facilitate the audio portion of today's interactive broadcast.
(Operator Instructions)
At this time I would like to turn the call over to Tryn Stimart as Chief Legal and Compliance Officer. You may proceed.
Thank you. Hello everyone.
Thank you for joining us for Abcellera's first quarter 2025 earnings call. I'm Tryn Stimart of Abcellera's chief legal and compliance officer. Dr. Carl Hansen of Abcellera's President and Chief Executive Officer, and Andrew Booth, of Abcellera's Chief Financial Officer, are joining me on today's call.
During this call, we anticipate making projections and forward-looking statements based on our current expectations and according to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.
Our actual results could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
